Fritextsökning
Artiklar per år
Innehållstyper
-
Grönt ljus för Getinges bolagsköp
Medicinteknikföretaget Getinge har fått godkännande från den amerikanska konkurrensmyndigheten Federal Trade Commission, FTC för köpet av bolaget Datascope Corp. Efter klartecken från amerikanska myndigheter kan den segdragna affären nu slutföras.
-
Major changes to the Q-Med board
The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.
-
Faster sales but less profits for Probi
The probiotic company increases its turnover, and the net results are twice as large as last year.
-
Swedish top scientists to EMBO
Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and one is from the University of Uppsala.
-
First ever study of human stem cell treatment
The FDA says yes to the world's first study in man of a human embryonic stem cell based therapy to treat spinal injury.
-
Teams up with leading dermatologist
Tripep has signed a letter of intent with a major Japanese specialty pharma company to bring their wound healing treatment to a big market.
-
Go ahead for leg wound study
Tripep starts a phase II-study of their wound healing joint venture project.
-
Test if you carry the fat virus
In a soon future there may be a quick and simple test that could show if you are infected with Ad-36, a human adenovirus that can make you over-weight.
-
Pfizer lays a chunky bid on Wyeth
The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal that may lead to lay-offs of some 8,000 persons.
-
Lundbeck divests companies
The company sells all shares in one listed company plus divests four small private equity funds, for a three-figured million sum.
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
New study of toxins and heart disease
Is there a correlation between exposure to hormone interfering environmental toxins and increased risk of developing cardiovascular disease? A new patient study will try to evaluate this, and one thousand people are to be included.
-
Success fee to Bioinvent and partner
The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.
-
New CEO to Promedvi
Sigrun Axelsson has taken on the leadership of the Lund-based medtech company.
-
Vitamin D is mental health aid
Vitamin D can help stave off the mental decline that can affect people in old age, a study suggests.
-
EUR 2 million for peanut allergies
ALK Abelló has signed an agreement to invest EUR 2 million in the French biotechnology company DBV Technologies.
-
Almost 150 will leave Coloplast
The Danish medtech company Coloplast negotiates headcount reductions, with a total number of almost 150 employees.
-
Biotage is regrouping
The Swedish company Biotage takes yet another step in streamlining efforts, by outsourcing all instrument production to contract manufacturers.
-
Vattenfall is firing with biomass
Vattenfall will provide Denmark with electricity by means of biomass.
-
Danisco first with green emulsifier
A new sustainable emulsifier from Danisco meets the increasing consumer demand for ethically correct consumer goods.
-
Danisco strengthens its IP team
Danisco's division Genencor has appointed a new Vice President of Intellectual Property Strategy and Chief IP Counsel.
-
Lytix calls in cash
Norwegian company Lytix Biopharma closes a USD 1.4 million funding round to finance new antimicrobial and oncology lead compounds.
-
Hormones make children fat
A new Danish million project will define the connection between hormons and obesity amongst children.
-
EU says yes to Roche drug
EU approves a first in class therapy for treatment of patients with moderate to severe form of rheumatoid arthritis.
BREAKING